Clinical Trial Update: Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating milademetan tosylate with low-dose cytarabine, with or without venetoclax, in recurrent or refractory acute myeloid leukemia; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Low-dose cytarabine (Cytarabine (low-dose))
• Milademetan Tosylate (milademetan-tosylate)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-06-15